{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:01:29Z","timestamp":1792101689458,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bmc.2020.115776","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T03:51:20Z","timestamp":1600746680000},"page":"115776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors"],"prefix":"10.1016","volume":"28","author":[{"given":"Fumihito","family":"Ushiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Amada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Tanaka-Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunoshin","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Masuko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2020.115776_b0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/ja.2017.124","article-title":"Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps","volume":"70","author":"Simpkin","year":"2017","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmc.2020.115776_b0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance\u2014the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2020.115776_b0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2042098614554919","article-title":"Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem","volume":"5","author":"Llor","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.bmc.2020.115776_b0020","unstructured":"O'Neill, J. Tackling Drug-Resistant Infections Globally: final report and recommendations. 2016."},{"key":"10.1016\/j.bmc.2020.115776_b0025","unstructured":"World Health Organization.Global Action Plan on Antimicrobial Resistance, 978 92 4 150976 3;World Health Organization:Geneva, Switzerland.2015."},{"key":"10.1016\/j.bmc.2020.115776_b0030","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013."},{"key":"10.1016\/j.bmc.2020.115776_b0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","article-title":"The 10 \u00d7 \u201820 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2020.115776_b0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1139\/cjm-2013-0089","article-title":"Is the GAIN Act a turning point in new antibiotic discovery?","volume":"59","author":"Brown","year":"2013","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.bmc.2020.115776_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2202","article-title":"Multi-targeting by monotherapeutic antibacterials","volume":"6","author":"Silver","year":"2007","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2020.115776_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bioorg.2015.07.004","article-title":"Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: a review","volume":"62","author":"Azam","year":"2015","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A New-Class Antibacterial\u2014Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2020.115776_b0060","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/cr4003984","article-title":"Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism","volume":"114","author":"Mayer","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2020.115776_b0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1568026033452500","article-title":"The ATP-binding site of type II topoisomerases as a target for antibacterial drugs","volume":"3","author":"Maxwell","year":"2003","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","article-title":"Exploiting bacterial DNA gyrase as a drug target: current state and perspectives","volume":"92","author":"Collin","year":"2011","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.bmc.2020.115776_b0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA TOPOISOMERASES: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2020.115776_b0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10409239109114072","article-title":"DNA gyrase: structure and function","volume":"26","author":"Reece","year":"1991","journal-title":"CRC Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.bmc.2020.115776_b0085","first-page":"377","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.bmc.2020.115776_b0090","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1101\/gad.872301","article-title":"Topoisomerase IV, alone, unknots DNA in E. coli","volume":"15","author":"Deibler","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmc.2020.115776_b0095","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"10.1016\/j.bmc.2020.115776_b0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1179\/joc.2011.23.2.87","article-title":"Characterization of the mechanisms of fluoroquinolone resistance in vancomycin-resistant enterococci of different origins","volume":"23","author":"L\u00f3pez","year":"2011","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.bmc.2020.115776_b0105","doi-asserted-by":"crossref","first-page":"e00020","DOI":"10.1128\/CMR.00020-18","article-title":"Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology","volume":"31","author":"Lakhundi","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bmc.2020.115776_b0110","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1073\/pnas.75.10.4838","article-title":"Energy coupling in DNA gyrase and the mechanism of action of novobiocin","volume":"75","author":"Sugino","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2020.115776_b0115","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/jac\/dkr247","article-title":"Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics","volume":"66","author":"Alt","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2020.115776_b0120","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1021\/jm500462x","article-title":"Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)","volume":"57","author":"Basarab","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0125","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1128\/AAC.05485-11","article-title":"Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents","volume":"56","author":"Eakin","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115776_b0130","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/jcph.1151","article-title":"A phase I, single-ascending-dose study in healthy subjects to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-2969b, a novel GyrB inhibitor","volume":"58","author":"Dennie","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2020.115776_b0135","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/acsmedchemlett.5b00196","article-title":"Discovery and characterization of a water-soluble prodrug of a dual inhibitor of bacterial DNA gyrase and topoisomerase IV","volume":"6","author":"O\u2019Dowd","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2020.115776_b0140","doi-asserted-by":"crossref","first-page":"e01503","DOI":"10.1128\/AAC.01503-18","article-title":"In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria","volume":"62","author":"Brown-Elliott","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115776_b0145","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.1021\/acsomega.0c00865","article-title":"Lead identification of 8-(methylamino)-2-oxo-1,2-dihydroquinoline derivatives as DNA gyrase inhibitors: hit-to-lead generation involving thermodynamic evaluation","volume":"5","author":"Ushiyama","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2020.115776_b0150","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1128\/AAC.50.4.1228-1237.2006","article-title":"In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class","volume":"50","author":"Mani","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115776_b0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/AAC.00596-06","article-title":"Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds","volume":"51","author":"Grossman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115776_b0160","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1021\/cb5003015","article-title":"General platform for systematic quantitative evaluation of small-molecule permeability in bacteria","volume":"9","author":"Davis","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2020.115776_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084409","article-title":"Tricyclic GyrB\/ParE (TriBE) Inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents","volume":"8","author":"Tari","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2020.115776_b0170","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0009-2614(99)00874-X","article-title":"Fragment molecular orbital method: an approximate computational method for large molecules","volume":"313","author":"Kitaura","year":"1999","journal-title":"Chem Phys Lett"},{"key":"10.1016\/j.bmc.2020.115776_b0175","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1039\/c2cp23784a","article-title":"Exploring chemistry with the fragment molecular orbital method","volume":"14","author":"Fedorov","year":"2012","journal-title":"PCCP"},{"key":"10.1016\/j.bmc.2020.115776_b0180","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1021\/jp0716740","article-title":"Extending the power of quantum chemistry to large systems with the fragment molecular orbital method","volume":"111","author":"Fedorov","year":"2007","journal-title":"J Phys Chem A"},{"key":"10.1016\/j.bmc.2020.115776_b0185","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2174\/156802612804910269","article-title":"GAMESS as a free quantum-mechanical platform for drug research","volume":"12","author":"Alexeev","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0190","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1021\/acs.jmedchem.6b00045","article-title":"Fragment molecular orbital method applied to lead optimization of novel interleukin-2 inducible T-cell kinase (ITK) inhibitors","volume":"59","author":"Heifetz","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0195","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acs.jcim.5b00644","article-title":"The fragment molecular orbital method reveals new insight into the chemical nature of GPCR\u2212ligand interactions","volume":"56","author":"Heifetz","year":"2016","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2020.115776_b0200","first-page":"5","article-title":"Development of an automated fragment molecular orbital (FMO) calculation protocol toward construction of quantum mechanical calculation database for large biomolecules","volume":"19","author":"Watanabe","year":"2019","journal-title":"Chem-Bio Inf J"},{"key":"10.1016\/j.bmc.2020.115776_b0205","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acs.jmedchem.5b01963","article-title":"Structure property relationships of carboxylic acid isosteres","volume":"59","author":"Lassalas","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0210","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/jm100087s","article-title":"Intramolecular hydrogen bonding in medicinal chemistry","volume":"53","author":"Kuhn","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0968-0004(99)01503-0","article-title":"GHKL, an emergent ATPase\/kinase superfamily","volume":"25","author":"Dutta","year":"2000","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bmc.2020.115776_b0220","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1021\/jm070562u","article-title":"Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases","volume":"50","author":"Graczyk","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0225","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.6b00850","article-title":"The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain","volume":"59","author":"Skerratt","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0230","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jep.2012.11.033","article-title":"In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action","volume":"145","author":"Asha","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bmc.2020.115776_b0235","doi-asserted-by":"crossref","first-page":"24481","DOI":"10.1016\/S0021-9258(20)80551-1","article-title":"Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions","volume":"268","author":"Peng","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0240","article-title":"Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne","author":"CLSI","year":"2019","journal-title":"PA: Clinical and Laboratory Standards Institute"},{"key":"10.1016\/j.bmc.2020.115776_b0245","article-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Tenth Edition. CLSI document M07\u2013A10. Wayne","author":"CLSI","year":"2015","journal-title":"PA: Clinical and Laboratory Standards Institute"},{"key":"10.1016\/j.bmc.2020.115776_b0250","article-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard\u2014Eighth Edition. CLSI document M11\u2013A8. Wayne","author":"CLSI","year":"2012","journal-title":"PA: Clinical and Laboratory Standards Institute"},{"key":"10.1016\/j.bmc.2020.115776_b0255","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/jcm.33.1.24-27.1995","article-title":"Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR","volume":"33","author":"Dutka-Malen","year":"1995","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bmc.2020.115776_b0260","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1093\/nar\/9.15.3589","article-title":"DNA gyrase: affinity chromatography on novobiocin\u2013Sepharose and catalytic properties","volume":"9","author":"Staudenbauer","year":"1981","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2020.115776_b0265","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1107\/S0021889897006766","article-title":"MOLREP: an automated program for molecular replacement","volume":"30","author":"Vagin","year":"1997","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.bmc.2020.115776_b0270","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"D53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2020.115776_b0275","unstructured":"Molecular Operating Environment (MOE), 2019.01; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018."},{"key":"10.1016\/j.bmc.2020.115776_b0280","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/jcc.540141112","article-title":"General atomic and molecular electronic structure system","volume":"14","author":"Schmidt","year":"1993","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0285","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jcc.20406","article-title":"The polarizable continuum model (PCM) interfaced with the fragment molecular orbital method (FMO)","volume":"27","author":"Fedorov","year":"2006","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2020.115776_b0290","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/qua.22068","article-title":"Efficient parallel algorithm of second-order M\u00f8ller-Plesset perturbation theory with resolution-of-identity approximation (RI-MP2)","volume":"109","author":"Katouda","year":"2009","journal-title":"Int J Quantum Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620306064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620306064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:11:30Z","timestamp":1760836290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089620306064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":58,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0968089620306064"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115776","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115776"}}